Bjarnason G A, Doyle N, Sone M, Beattie K, Elia J, Owens B
Toronto-Sunnybrook Regional Cancer Center, North York, Ontario, Canada.
J Infus Chemother. 1995 Spring;5(2):82-8.
The CADD-Micro System (Sims Deltec, St. Paul, MN) was formally evaluated in patients with metastatic renal cell cancer, participating in a phase-III study comparing a 2-week circadian versus flat infusion of FUDR. Ten patients participated, 2 receiving five cycles of FUDR by a flat infusion, and 8 receiving 12 cycles of FUDR by circadian infusion. A total of 235 treatment days were evaluated. All patients had a Port-A-Cath in place for venous access. The patients completed a structured evaluation survey for each week of treatment regarding their interaction with the pump and an overall evaluation of the system and the patient information guide at the end of each 2-week course. Nurses from our home infusion program completed a separate evaluation. Overall patient and clinician perception of this pump was excellent. The main drawback had to do with the design of the battery compartment cover and the handling of the drug reservoir. The small size of the drug reservoir (10 mL) limits the usability of this pump to low-volume tasks.
CADD-Micro系统（Sims Deltec公司，明尼苏达州圣保罗）在转移性肾细胞癌患者中进行了正式评估，这些患者参与了一项比较氟尿苷2周昼夜输注与匀速输注的III期研究。10名患者参与，2名通过匀速输注接受5个周期的氟尿苷治疗，8名通过昼夜输注接受12个周期的氟尿苷治疗。共评估了235个治疗日。所有患者均植入了Port-A-Cath导管用于静脉通路。患者在治疗的每周完成一份关于他们与泵的相互作用的结构化评估调查问卷，并在每2周疗程结束时对系统和患者信息指南进行总体评估。我们家庭输液项目的护士完成了一份单独的评估。患者和临床医生对该泵的总体评价很好。主要缺点与电池仓盖的设计和药物储液器的操作有关。药物储液器体积小（10 mL），限制了该泵在小容量任务中的可用性。
